Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Repeated Dose Strategy for SARS-CoV-2 Vaccination in Kidney Transplant Patients A Prospective, Randomized Multicenter Study by the REnal Patients COVID-19 VACcination (RECOVAC) Consortium

NCT05030974 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT05030974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05030974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Repeated Dose Strategy for SARS-CoV-2 Vaccination in Kidney Transplant Patients A Prospective, Randomized Multicenter Study by the REnal Patients COVID-19 VACcination (RECOVAC) Consortium
Lead sponsor
University Medical Center Groningen
Phase
Phase 4
Overall status
Completed
Start date
October 21, 2021
Completion date
March 12, 2022
Enrollment
336 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, kidney diseases, sars-cov2 infection, vaccine response impaired